Trevena, Inc. (TRVN), a biopharmaceutical company, on Tuesday announced that it has met the minimum bid price requirement set by the Nasdaq Stock Market LLC. As a result, Trevena's stock will continue to be listed on the Nasdaq Capital Market.
The company said it plans to release data from the clinical proof-of-concept studies for TRV045. Additionally, the company anticipates clinical outcomes from a study involving approximately 200 patients. In the regular trading session on Friday the stock closed at $1.15, up $0.07 or 6.48%. However, during the premarket trading, the stock is currently trading at $1.1410, down $0.01 or 0.78%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.